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The evolution of intestinal transplantation has distantly paral-
leled that for kidney and liver transplantation. Though the 
introduction of cyclosporine made other organ transplants a 
clinical reality, success with intestinal transplantation re-
mained almost nonexistent due to a high incidence of graft 
loss from rejection, infection, and technical complications_ I 
The experimental studies on intestinal transplantation, re-
ported by Lillehei and colleagues in 1959 as an isolated organ 
graft in dogs' and subsequently by Starzl and Kaupp with the 
multivisceral graft in dogs (liver. stomach. pancreaticoduode-
nal complex. small and large intestine),j supported a unidirec-
tional paradigm of transplantation and immunology similar to 
that found after bone marrow transplantation. 4 These experi-
ments predicted that graft-versus-host disease (GVHD) would 
be precipitated through the immunocytes in the lymphoid-
rich major histocompatibility complex (MHC) disparate intesti-
nal allografts. 5 
Numerous attempts at clinical intestinal transplantation, per-
formed after 1964 under azathioprine and steroid and subse-
quently cyclosporine immunosuppression, were largely unsuc-
cessful. In 1987, a 3-year-old girl received a multivisceral 
abdominal graft that contained the stomach. duodenum, pan-
creas, small bowel. colon, and liver; she had an extended 
survival of 6 months with good intestinal graft function. 6 
A modified application of this operation was the transplanta-
tion of a "cluster" of organs in 1989.' This allograft consisted 
of liver and pancreaticoduodenal complex used after upper 
abdominal exenteration for malignancy (Fig. 184-1). Viability 
of varying lengths of intestine with these clusters was proven. 
as was evidence of regeneration after severe rejection-induced 
injury. The inclusion of the liver in this type of graft was 
believed to protect the other organs transplanted from the 
same donor against rejection.H .• Consequently, an even longer 
survival of 1 year was obtained in a recipient of a liver and 
small-bowel graft treated by Grant and associates. 10 Until 1990, 
there had been only two survivors of isolated cadaveric intesti-
nal grafting." Il 
The success of the new immunosuppressant tacrolimus (FK-
506 [PrografJ) in 1989 after clinical trials with liver and kidney 
transplantation allowed the transplantation of human intesti-
nal grafts (alone or a part of a multivisceral graft) almost with 
routine success. I.' " Successful intestinal transplantation then 
permitted the appreciation of the two-way paradigm of trans-
plantation immunology"; it was postulated that two cell popu-
lations (of recipient and donor origin) reciprocally modulate 
immune responSiveness (host-versus-graft and graft-versus-
host), including the induction of mutual nonreactivity with 
consequent organ allograft acceptance. «. 
INDICATIONS 
Loss of intestinal function may be acute (e.g., necrotizinR 
enterocolitis. volvulus. mesenteric thrombosis) or chronic 
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Figure 184-1. Cluster allograft (sbaded portion), including the 
liver, pancreas, and duodenal segment of small intestine. (From 
Starzl TE, Todo S, Tzakis A, et al: Abdominal organ cluster 
transplantation for the treatment of upper abdominal malignancies. 
Ann Surg 1989; 210:374-386.) 
(e.g., Crohn's disease, radiation enteritis). Disease classifica-
tion can be better viewed with an arbitrary division of surgi-
cal (short gut) and nonsurgical etiologic factors. Patients with 
surgical causes generally suffer from loss of bowel length 
after resections for atresias, infarctions (e.g., volvulus, vascular 
catastrophes, necrotizing enterocolitis), or strictures and fistu-
las as with Crohn's disease. With nonsurgical causes of intesti-
nal failure, the anatomic length and gross morphology may be 
normal. These causes include motility disorders (e.g., intesti-
nal pseudo-obstruction, Hirschsprung's disease), absorptive in-
sufficiencies (e.g., microvillus inclusion disease), polyposis 
syndromes, and "incarcerating" desmoid tumors. 
Total parenteral nutrition (TPN) is the standard of care for 
patients who are unable to maintain a normal nutritional state 
by use of the gastrointestinal tract alone (intestinal failure).'7 
Transplantation of the intestine, either alone or accompanied 
by other intra-abdominal organs (liver, stomach, pancreas), 
may be beneficial in patients who do not respond to this 
therapy. The stability and duration of TPN support are vari-
able, and failure of TPN can manifest with complicating fac-
tors, such as infection, metabolic disorders. difficulty with 
vascular access (from extensive venous thrombosis). and liver 
cirrhosis with end-stage liver disease. 'I11is has resulted in an 
inestimable rate of morbidity and mortality. 
The decision regarding allograft composition focuses on the 
integrity of the remaining gut and other abdominal organs, 
both functionally and anatomically. Guidelines used in substan-
tiating the need for concomitant liver replacement in these 
intestinal transplantatiOn candidates are: 
• Biochemical dysfunction (hyperbilirubinemia. transami-
nase abnormalities. hypoalbuminemia. and coagulopathy) 
• Pathologic processes (fibrosis or cirrhosis on liver biopsy) 
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TABLE 184-1. Partial and Complete Intestinal Allografts 
Organ Transplanted 
Multivisceral (stomach, 
duodenum. pancreas. liver, 
small bowel, colon) 
liver and small intestine 
liver, duodenum, and pancreas 
(organ cluster transplantation) 
Small intestine 
Indication 
Pseudo-obstruction/aganglionosis 
syndrome with hepatic failure; 
diffuse splanchnic venous 
thrombosis and hepatic failure 
Hepatic failure after prolonged 
hyperalimentation for short 
gut syndrome 
After upper abdominal 
exenteration for malignancy 
Congenital or acquired absence 
or dysfunction 
The clinical presence of portal hypertension, as mani-
fested by hepatosplenomegaly, asCites, or esophageal vari-
ces and portal hypertensive gastroenteropathy 
Patients deficient in protein S: protein C, and antithrombin 
III (Iiver-derived) may be candidates for a combined liver/small 
intestine allograft in the absence of clinical liver disease. 18 
Recipients lacking these substances experience diffuse throm-
boses within the splanchnic system and undergo transplanta-
tion for mesenteric venous hypertesion rather than for intesti-
nal failure. Patients with motility disorders or neoplasms that 
involve extensive lengths of the gastrointestinal tract are also 
candidates for replacement of this entire system (fable 184-1). 
Table 184-2 lists the causes of intestinal failure in patients 
who have undergone transplantation at the University of Pitts-
burgh. Inability to continue TPN because of the development 
of hepatic cirrhosis or venous access limitations were the 
most frequent indications for transplantation. 
ABDOMINAL VISCERAL 
PROCUREMENT 
The grafts were obtained from ABO-blood type identical brain-
dead donors; matching of human leukocyte antigen (HLA) was 
random. No attempts were made to modulate the lymphoid 
tissue in the intestinal allograft by either irradiation or anti-
lymphoid antibody treatment. University of Wisconsin solu-
tion was used for graft preservation. 
The safe procurement of multiple visceral organs, either en 
bloc or as separate components, hinges on a few fundamental 
precepts. Conceptually, the focus is to isolate and cool the 
organs. thus preserving their vascular and parenchymal anat-
omy and function. Multivisceral en bloc retrieval, induding 
the stomach, duodenum, pancreas, liver, and small intestine, 
TABLE 184-2. Indications for Composite and Isolated 
Intestinal Transplantation in 98 Patients at the University of 
Pittsburgh (May 1990 to August 1997) 
Pediatric Patients (60) Adult Patients (38) 
Necrotizing enterocolitis 6 Crohn's disease 8 
Gastroschisis 16 ThrombotiC disorder 13 
Volvulus 15 Trauma 7 
Pseudo-obstruction 6 Pseudo-obstruction 
Hirschsprung's disease 4 Radiation enteritis I 
Intestinal atresia 8 Desmoid tumor 4 
Microvillus indusion ; Familial polyposis 1 
disease Volvulus 
Trauma Gastrinoma 
Intestinal polyposis Ulcerative colitis 
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is the parent operation, and the assembled components have 
been likened by Starzl and colleagues to a large clwnp of 
individual grapes from the whole. 19 An appreciation of the 
fundamental strategy of multivisceral organ retrieval leads to 
an understanding of the lesser variant operations (Le., liver, 
small intestine, combined liver/small intestine, and organ 
cluster-liver, duodenwn, and pancreas-transplantation). A 
more complete discussion of the specifics of organ procure-
ment is presented in Chapter 177. 
RECIPIENT OPERATIONS 
Most patients who need intestinal or multiorgan replacements 
have undergone multiple forays into the abdominal cavity for 
intestinal resections, lengthening procedures, and treatment 
of complications. This results in volwne contraction of the 
abdominal cavity and severe adhesions. Consequently, the or-
gans of the donor need to be smaller than those of the 
recipient to ensure proper abdominal closure. This allows for 
donor weight discrepancies of usually no greater than 20% 
than the recipient weight unless graft reduction can be surgi-
cally accomplished. 
Previous operations may complicate the removal of the 
recipient'S organs, especially if cirrhosis, portal hypertension, 
or inferior vena caval thromboses are present, all of which 
may be sequelae of the original disease or of prior operations. 
The recipient operation consists of removal of the failed or-
gans with exposure of the vascular anatomy and, finally, allo-
graft implantation. Following is a brief description of the 
salient features of the recipient operations. 
Multivisceral Transplantation 
After abdominal exenteration and exposure of the retroperito-
neal aorta and inferior vena cava have been performed, the 
multivisceral graft (Fig. 184-2A) is connected by its vascular 
attachments: first the suprahepatic attachment, then infrahe-
patic vena caval connections (or ·piggyback" to the skele-
tonized recipient vena cava), and finally the arterioaortic anas-
tomosis (using an aortic interposition homograft). The 
recipient's portal vein and its inflow organs (gastrointestinal 
tract, pancreas, and liver) are removed with the enterectomy. 
The donor portal vein retains its continuity via the liver in the 
procurement of the allograft; thus, no portal vein anastomosis 
is required in this procedure. Patients with a normal native 
liver can receive a modified multivisceral procedure that ex-
cludes the allograft liver as part of the composite of organs, 
with portal venous return directed into the recipients portal 
vein (Fig. 184-28). 
Restoration of intestinal continuity requires an esophagogas-
tric anastomosis and a coloenteric anastomosis with the distal 
ilewn allograft. Initially, the patient also receives an ileostomy. 
Takedown of the ileostomy can be perfortned after several 
months, when oral nutrition is consistently adequate, a stable 
immunosuppressant regimen has been achieved, and there is 
no further need for frequent endoscopic surveillance. 
Liver and Small Bowel 
Uver and small intestine are removed in these patients, but 
the remainder of the foregut (stomach, duodenwn, pancreas) 
is retained. When possible, the liver is removed with the 
retrohepatic vena cava preserved in situ.lo 
After the enterectomy, the composite allograft is implanted 
by anastomosing the suprahepatic vena cava of the donor, 
including the hepatic veins (so-called piggyback liver trans-
plantation) end-to-side to the recipient'S vena cava; the donor 
infrahepatic vena cava can then be ligated (Fig. 184-3.4). The 
double arterial stem of the celiac and superior mesenteric 
arteries (via the Carrel patch technique) is connected to the 
infrarenal aorta (with an aortic conduit or iliac artery homo-
graft), with subsequent graft reperfusion. Because the axial 
stem of the portal vein between the donor organs has re-
mained intact, all that is required for the completion of portal 
flow is attachment of the portal vein of the remnant foregut 
in the recipient to the intact portal stem of the donor. This 
may not be possible, however, because of size discrepancy or 
difficult anatomic relationships between donor and recipient 
portal veins. In this case, a pennanent portocaval shunt is 
perfortned (Fig. 184-38). The intestinal anastomoses are then 
Figure 184-2. Diagrams of 
multivisceral donor organs: 
complete multivisceral (A) and 
modified multivisceral (8). (From 
Reyes J, Bueno J, Kocoshis S, et a1: 
Current statuS of intestinal 
transplantation in children. J 
Pediatr Surg 1998; 33:243-254.) 
e 
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Figure 184-3. Modifications of the liver/small intestinal allograft. 
A, Combined liver/small intestinal allograft. 
B, Systemic porta caval shunt or recipient portal vein to donor portal vein shunt (Inset) allows venous outtlow of retained pancreas and 
stomach from recipient. (From Reyes J, Bueno J, Kocoshis S. et al: Current status of intestinal transplantation in children. J Pediatr Surg 1998; 
33:243-254.) 
C. Composite liver and intestine graft with preservation of the duodenum in continuity with the graft jejunum and hepatic biliary system. 
The aUograft pancreas is transected to the right of the portal vein. (From Abu-Elmagd K. Reyes J. Todo S. et al: Clinical intestinal 
transplantation: New perspectives and immunologic considerations. J Am Coli Surg 1998; 186:512-527.) 
D, In situ split liver graft that maintains the left lateral segment in continuity with the hepatic hilus and duodenum, with transection of 
allograft pancreas. (From Reyes J, Fishbein T. Bueno J. et al: Reduced sized onhotopic composite liver. Intestinal allograft: Rationale and In situ 
split technique in an initial experience. Transplantation 1998: 66:489-492.) 
completed with a proximal jejunojejunostomy. an ileocolos-
tomy. a temporary distal ileostomy, and a Roux-en-Y biliary 
anastomosis. 
To avoid a biliary anastomosis (with its potential for compli-
cations). a modification of the original "cluster" allograft. as 
depicted in Figure 184-1, has been applied to the liver/small-
bowel allografts. Here. the allograft duodenum remains in 
continuity with the allograft biliary system and varying lengths 
of allograft jejunum-ileum (Fig. 184-3(.'). In one such graft. a 
reduced segment of allograft liver (the left lateral segment) 
was successfully used after an in situ split was performed to 
overcome a donor-recipient size mismatch in a critically ill 
pediatric recipient (Fig. 184-3D). 
Isolated Small Bowel 
In cases of surgical shon gut. the proximal and distal remnants 
of the intestine are identified; when there is functional disease 
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Figure 184-4. A, Arterialization and potential venous drainage options of the isolated small intestine allograft. B. Isolated small·bowel graft; 
the distal ileal chimney allows easy access to bowel mucosa. PV = portal vein; SV = splenic vein; SMV = superior mesenteric vein; lYe = 
interior vena cava. (From Reyes J. Bueno J. Kocoshis S. et ali Current status of intestinal transplantation in children. J Pediatr Surg 1998; 
:33:243-254.) 
or neoplasm. the recipient's diseased small intestine is re-
moved. The superior mesenteric artery of the donor bowel is 
sewn to the infrarenal aorta, and the donor superior mesen-
teric vein to the recipient portal vein, superior mesenteric 
vein, splenic vein, or inferior vena cava (Fig. 184-4A). This 
may be facilitated by the use of an interposition venous graft. 
Reperfusion of the intestinal graft is effected after the vascular 
anastomoses. Intestinal continuity is completed with proximal 
and distal anastomoses, and access to the ileum for endo-
scopic examination is provided by a temporary "chimney" 
ileostomy (Fig. 184-4B).2I 
Cold ischemia refers to the time between procurement and 
implantation of the allograft and has ranged from 2.8 to 17 
hours. Warm ischemic time for the allograft (sewing-in time) 
is about 30 minutes and is also a determinant of preservation 
injury to the intestine. In an attempt to reduce graft dysmo-
tility. a segment of large intestine was included in 32 allografts. 
This technique was abandoned after 1994. and subsequently 
the enteric and celiac ganglia have been preserved for the last 
16 grafts. 
IMMUNOSUPPRESSION 
Immunosuppression is similar in recIpIents of small-bowel. 
liver/small bowel. duster. and multivisceral transplants. Intra-
venous methylprednisolone is given immediately after graft 
reperfusion (I g in adults. 10 mg/kg in children). Administra-
tion of tacrolimus (0.1 S mg/kg/day) is then begun by continu-
ous intravenous infusion. with steady-state whole blood levels 
(microparticle enzyme immunoassay) between 1 S and 25 ng/ 
mL as targets. A steroid taper of methylprednisolone is started 
at a dose of <; mg/kg/day (tor children) or 200 mg/day (for 
ildults) and reduced over a period of <; days to 1 mg/kg/ 
Jav (for children) or 20 mg/day (for adults). In some cases. 
azathioprine may be added to mitigate the nephrotoxicity and 
neurotoxicity of tacrolimus. A series of 23 patients completed 
a trial of cyclophosphamide (Cytoxan), which was given at a 
dose of 2 mg/kg/day for 4 weeks. The patients were then 
switched to mycophenolate mofetil (1 S to 30 mgikg/day) or 
azathioprine (1 to 2 mg/kg/day). As gastrointestinal motility 
resumes, oral tacrolimus given twice daily may be used to 
supplement the intravenous regimen, which is gradually ta-
pered. 
Induction therapy as well as chronic maintenance therapy 
involves the use of two and often three drugs. If organ toler-
ance with minimal rejection episodes is demonstrated, how-
ever. gradual reduction and even cessation of steroid therapy 
may be possible. 
Prostaglandin E, (prostin) is administered, 0.003 to 0.009 
mg/kg/min. for the first 5 postoperative days. This is given for 
its beneficial effects on renal perfusion as well as its preven-
tion of microvascular thromboses, the damage-mediating event 
in acute cellular rejection and procurement injury.ll Rejection 
was treated with optimization of tacrolimus level, supplemen-
tal steroids, and, if necessary, OKT3. 
BONE MARROW AUGMENTATION 
The phenomenon of donor and recipient cell migration ob-
served in this patient population was later conlirmed to occur 
after transplantation of all solid organs. ll1ese "chimeric" com-
posites form the basis of the two-way paradigm of transplanta-
tion immunology, with mutually canceling effects of donor 
and recipient cell populations producing eventual allograft 
acceptance. I' According to this hypothesis. augmentation of 
leukocyte chimerism was pertormed with unaltered adjuvant 
donor bone marrow cells recovered from donor thoracolum-
bar vertebral bodies and infused postoperatively in a single 
infusion of 3 to <; x 10" cells/kg body weight. as previously 
described. >.1. 2. 
I; 
I 
i 
Monitoring of chimerism (the presence of donor cells) was 
performed serially after transplantation using the recipient's 
peripheral blood by either_ flow cytometry or polymerase 
chain reaction (PCR)!5 Graft-versus-host disease (GVHD) sur-
veillance was studied in all suspected skin and gastrointestinal 
lesions by routine histology, with the detection of donor cells 
by immunohistologic staining for donor-specific human leuko-
cyte antigen (HLA) antigens, and in situ hybridization tech-
nique using the Y-chromosome-specific probe, as previously 
described. " 
POSTOPERATIVE CARE 
Recipients of multivisceral, liver/small-bowel, or cluster grafts 
commonly suffer from severe liver failure. Therefore, the care 
with respect to lungs, infection surveillance. and liver graft 
function is similar to that for routine liver transplant recipi-
ents. Recipients of isolated small-bowel transplants who 
have stable liver function have a lesser preoperative medi-
cal acuity. 
Ventilatory Management 
Extubation can often be accomplished within 48 hours of 
transplantation. Unusual circumstances, such as graft malfunc-
tion. sepsis, inability to close the abdominal wall. and severe 
preoperative hepatic failure, may prevent early extubation. 
Because the operation is quite long (8 to 18 hours) and the 
patients are often in a weakened nutritional state preopera-
tively, a careful assessment of weaning parameters is reqUired. 
The inspiratory force, forced vital capacity, and spontaneous 
minute ventilation are most important. It is wise to observe 
the patients for several hours while they remain intubated on 
continuous positive airway pressure (CPAP) to make certain 
that they can tolerate the withdrawal of mechanical support 
and extubation. 
Incisional pain. ascites, and pleural effusions may compro-
mise ventilation and the ability to cough. Muscle wasting 
and malnutrition. partial or complete paralysis of the right 
hemidiaphragm. 'u and occasional discrepancies in donor-recip-
ient size that produce an increased intra-abdominal volume 
with compression of the thoracic cavity may be factors re-
sponsible for respiratory impairment. These patients often 
require low doses of intravenous narcotics. repeated thoracen-
tesis and paracentesis. and supplemental extensive respiratory 
therapy if they are to avoid the need for reintubation. 
Many patients have required tracheostomies because of the 
need for prolonged ventilatory support. Rarely (two cases), 
severe rejection of isolated small intestine allografts with sys-
temic venous drainage into the inferior vena cava has been 
heralded by respiratory insufficiency and picture of acute 
respiratory distress syndrome (ARDS). 
Renal Function 
Most intestinal transplant candidates have experienced some 
measure of renal injury due to multiple episodes of infection. 
antibiotic requirements. and liver failure. Early after trans-
plantation. there is significant interstitial accumulation of fluid 
into the graft. lung. and peripheral tissues; this accumulation 
peaks at -i8 to 72 hours. Extensive volume shifts into the 
transplanted bowel (related to preservation injury) and heavy 
ascites production (related to mesenteric lymphatic leakage) 
lead to intravascular volume depletion and can exacerbate the 
nephrotoXicity of tacrolimus and certain antibiotics. Continu-
IlUS central venous pressure measurement. often tor weeks 
following transplantation. provides important in!ormation for 
maximizing gr.lft perlusion and preserving the integrity of the 
---------_ .. -
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kidneys. Two children have undergone inclusion of an allo-
graft kidney with their primary intestine transplant, and one 
long-term pediatric survivor has required sequential kidney 
transplantation. 
Infection Control 
Recipients of isolated or composite small-bowel grafts receive 
prophylactiC. broad-spectrum intravenous antibiotics. Any his-
tory of recent nosocomial infections before transplantation 
should be addressed with the administration of appropriate 
specific antibiotics. Colonizing organisms growing from enter-
ocutaneous fistulous tracts should be treated perioperatively. 
All recipients are given a preoperative and postoperative 
"cocktail" of oral nonabsorbable antibiotics every 6 hours for 
2 weeks; the mix includes amphotericin B, gentamicin, and 
polymyxin E and is intended to achieve selective bowel decon-
tamination. 27 Surveillance stool specimens are obtained for 
culture weekly. When organisms grow in quantitative cultures 
to colonies of greater than 10" organisms in the presence of 
signs of systemic sepsis, or ongoing acute cellular rejection of 
the allograft, specifically directed intravenous antibiotics are 
added to the reginlen to treat the presumed translocating 
organisms. This most commonly occurs during episodes of 
acute rejection, when the mucosal barrier of the allograft has 
been immunologically damaged; however. it may also be seen 
with enteritis associated with Epstein-Barr virus (EBV).28 
The antiviral prophylactiC strategy has evolved during this 
study period and presently includes a 2-week course of intra-
venous ganciclovir with concomitant CMV-specific hyperim-
mune globulin (Cytogam).29 Lifetime oral trimethoprim-sulfa-
methoxazole is used as prophylaxis for Pneumocystts carintt 
pneumonia. 
Nutritional Support 
Full nutritional support is initially provided via standard TPN. 
TPN is tapered gradually as oral or enteral feedings (via gastric 
or jejunal tube) are advanced. Tube feedings are initiated 
with an isotonic dipeptide formula containing medium-chain 
triglycerides and glutamine. This formula is later converted to 
a lactose-free and gluten-free diet that contains dietary fibers 
to promote normalization of intestinal motility and function. 
Most patients do not voluntarily eat adequate amounts early 
after the oper.ltion. and variations to this existed among the 
various intestinal transplant cohorts. Most impressive has been 
the resistance to resumption of oral feedings in pediatric 
recipients.'''' Therefore. enteral supplementation is required 
when the intestinal tract becomes functional. Management is 
highly "individualized." since the Simplicity of an uneventful 
post-transplantation course may suddenly change with any 
surgical or immunologic complication. These complications 
can be manifested with serious t1uid. caloric, protein, and 
trace element deficits. 
Assessment of Graft Status 
A judgment of the anatomic and functional integrity of the 
graft begins in the operating room. The normal appearance of 
the mesentery and intestine is pink and nonedematous. with 
the intestine occasionally demonstrating contractions. Alter-
ations from this appearance can be observed in the operating 
room and in the ileal stoma postoper,ltivdy. 
Surveillance of intestinal gr.lft rejection focuses on clinical 
evaluation and gross morphologic examination of the stoma 
and the distal ileum. Frequent routine enteroscopic surveil-
lance has been the most reliable tool for the early diagnosis 
of intestinal rejection." Endoscopic evaluations are pertormed 
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routinely twice a week through the allograft ileostomy; upper 
endoscopy is performed when clinical changes are not eluci-
dated by distal allograft evaluation. Grossly, the bowel reacts 
to insult in nonspecific ways with edema, cyanosis, conges-
tion, and increased stomal output; these alterations should 
signal a broad differential to include preservation injury, sys-
temic sepsis, rejection, and enteritis. 
The stomal output is assessed for volume, consistency, and 
the presence of reducing substances, which can be seen in 
the event of rejection, bacterial overgrowth, or malabsorption. 
Typical stomal output of a clear, watery effluent within the 
first week of implantation is 1 to 2 I.Jday for adults and 40 to 
60 mUkg/day for children. If these volumes are exceeded and 
no significant pathology is present, paregoric, loperamide, 
pectin, somatostatin, or oral antibiotics may be used singly or 
in combination to control the diarrhea. The presence of blood 
in the stool is always an ominous sign and indicates rejection 
until proven otherwise. 
Serum tests are imponant in assessing injury to the liver 
(bilirubin, aspartate aminotransferase, and alanine aminotrans-
ferase), but no such tests exist for the intestinal grafts. Serum 
markers for nutritional adequacy and anabolic status (trans-
ferrin, albumin, retinoic acid) are of limited value, whereas 
specific tests of the absorptive ability of the graft are good 
measures of overall function. Assessment of small-bowel func-
tion relies on absorption studies of n-xylose and tacrolimus 
and on the quantitation of fat in the stool. Most patients show 
satisfactory absorption curves for n-xylose within the first 
postoperative month, with absorption improving over time. 
Abnormal results obtained after 1 month should always 
prompt an aggressive search for underlying pathology, espe-
cially rejection. 
The maintenance of satisfactory tacrolimus whole blood 
trough levels of 15 to 25 ng/mL with oral therapy alone is a 
good indicator of adequate absorption. In our patients, this 
level has occurred at a mean of 28 days after transplantation 
and tends to be delayed longer in recipients of multivisceral 
grafts." The excretion of fat in the stool has been abnormal 
in almost all patients, but clinical steatorrhea has not been 
a problem. 
Radiologic evaluations by standard barium gastrointestinal 
examination are valuable in assessing mucosal pattern and 
motility and are performed roUtinely after the first postopera-
tive week. A normal mucosal pattern is expected. Intestinal 
transit time is about 2 hours. Intestinal graft rejection, when 
mild, can be suspected when evidence of mucosal edema 
exists. Severe rejection, with exfoliation of the mucosa, ablates 
the normal mucosal pattern and can be seen as segments of 
"tubulized" intestine and strictures (Fig. 184-5). 
COMPLICATIONS 
Before the various potential complications are described, it is 
important to impart a general perspective on the care of these 
patients. Comprehensive management of intestinal reCipients 
requires a multidisciplinary approach by surgeons. anesthesiol-
ogists. nurses. critical care physicians. pathologists. and a host 
of internal medicine subspecialists. Easy access to diagnostic 
and therapeutic modalities is paramount. including mechani-
cal ventilation. hemodialysis, bronchoscopy, gastrointestinal 
endoscopy, thromboelastography, percutaneous cholangiogra-
phy. ultrasonography, invasive and noninvaSive contrast radiog-
raphy, and sophisticated hemodynamic monitoring systems. 
More impOrtant than the preceding, however, is a vigilance 
about patient care and attention to detail on the part of 
both phYSicians and nurses. Problems in these patients can 
originate from a multiplicity of sources. We can make several 
Jssumptions about these patients based on our experience: 
Figure 184-5. Severely damaged allograft intestine in a recipient of 
a liver-small bowel after multiple episodes of rejection. Diffuse 
tubullzed gut, strictures. and significant distention of the native 
duodenwn are seen. 
1. Preoperative deterioration of physical performance sta-
tus predisposes to various organ system failure that persists in 
the postoperative period even though allograft function may 
be acceptable. 
2. Treating transplant recipients is a labor-intensive task, 
requiring aggressive respiratory therapy, nutritional and antibi-
otic support. fluid management. and nursing care, often for 
prolonged periods in the intensive care unit. 
3. Immunotherapy doses in patients with multlvisceral 
transplants tend to be higher than in patients with single 
organ transplants. 
4. Most patients experience episodes of infection and rejec-
tion after transplantation. often concomitantly. Any subjective 
complaints or objective abnormalities should be vigorously 
pursued until a cause is found or until these problems resolve . 
Graft Rejection 
Intestinal allograft rejection can present as an array of symp-
toms that include fever. abdominal pain. distention. nausea. 
VOmiting, and a sudden increase in stomal output. The stoma 
may become edematous. erythematous. and friable. Gastroin-
testinal bleeding can occur in cases of severe uncontrollable 
rejection in which ulcerations and sloughing of the intestinal 
mucosa occur. Septic shock or ARDS may develop. Bacterial 
or fungal translocation can occur during intestinal allograft 
rejection as a result of disruption of the intestinal mucosal 
barrier. Gut decontamination must be instituted during these 
episodes. H 
Endoscopically. the transplanted intestinal mucosa loses its 
velvety appearance. It may become hyperemiC or dusky as 
well as hypoperistaltic. Erythema may be focal or diffuse. The 
mucosa becomes friable. and diffuse ulcerations appear (Fig. 
184-6) (see Color Plate). 
I ; 
-Figure 184-6. A. Nonnal endoscopic appearance of the 
transplanted small intestine. B. Moderate acute cellular 
rejection of an intestinal allograft demonstrating diffuse 
edema and focal erythema. (See Color Plate.) 
Histologically, there is variable presence of lamina propria 
edema and villous blunting. However, the mononuclear cell 
infiltrates and cryptitis with apoptosis and regeneration are 
necessary for establishing the diagnosis of rejection. Neutro-
phils, eosinophils. and macrophages may be seen traversing 
the muscularis mucosa.34. 3' The degree of epithelial and crypt 
cell damage varies. Complete mucosal sloughing and crypt 
destruction are seen in grafts with severe rejection. The muco-
sal surface is partially replaced by inflammatory pseudomem-
branes and granulation tissue (Fig. 184-7). This event may 
precipitate continuous blood loss as well as intermittent septic 
episodes from the damaged intestine. 
Chronic rejection has been observed in patients with persis-
tent intractable rejection episodes. Clinically progressive 
weight loss, chronic diarrhea. intermittent fever. and gastroin-
testinal bleeding dominate the presentation. Histologically. vil-
lous blunting, focal ulcerations, epithelial metaplasia. and 
scant cellular infiltrate are present on endoscopic mucosal 
biopsies. Full-thickness biopsy specimens show obliterative 
thickening of intestinal arterioles. 
The incidence of acute intestinal allograft rejection during 
the first 90 days after transplantation is reported to be 92% in 
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isolated small-bowel transplant recipients and 66% in recipi-
ents of composite graft (multivisceral. liver/small bowel), sug-
gesting that the liver is "protective" of the intestine. as seen 
experimentally.8. l6 Interestingly, the incidence of acute liver 
allograft rejection in reCipients of composite grafts is 43%, a 
rate similar to that seen after isolated liver transplantation.30 
Mild graft rejection is treated initially with intravenous 
methylprednisolone; moderate or severe rejection is treated 
with a methylprednisolone taper. Tacrolimus trough levels in 
whole blood should reach 15 to 25 ng/mL by either the 
oral or intravenous route. OKT3 is used when rejection has 
progressed with a steroid taper; however. it should be enter-
tained as the initial therapeutic agent in cases of severe muco-
sal injury and crypt damage. The use of cyclophosphamide-
mycophenolate mofetil induction therapy or bone marrow 
augmentation has had no beneficial effect on the frequency 
of rejection.30. l6 
Postoperative Hemorrhage 
Coagulopathy is more often an intraoperative problem that 
relates to liver dysfunction, qualitative and quantitative plate-
Figure 184-7. Acute ceUular rejection. A. Endoscopic biopsy obtained 14 days after transplantation showed widening of the lamina propria 
with increased mononuclear ceUs. which were often cuffed around small vessels and infiltrating the crypt epithelium (UITOU'). (Hematoxylin 
and eosm. X 140.) B. The reaction was more intense in biopsy specimens that contained lymphoid nodules and where blast~enesis. focal 
ulcerations. congestion. and neutrophil plulQPng of capillaries were also seen (moderate acute ceUuIar rejection). (Helll3toxylin and eosin. 
X 140.) c: UncontroUed acute rejection eventually resulted in widespread mucosal destruction: the mucosa was replaced by granulation tissue. 
Note the overlying inflammatory pseudomembrane (arrow). (Hematoxylin and eosin. X :ISO.) 
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let defects, and fibrinolysis. 37 Intraoperative bleeding is fur-
thered by vascularized adhesions from previous surgery and 
portal hypertension. Temporary graft reperfusion coagulopa-
thy mediated by plasminogen activators from the graft may 
occur.38 Efforts are taken to normalize these global aspects of 
coagulation by the end of the operative procedure, so that in 
the absence of liver dysfunction, the coagulopathy is usually 
minor in the postoperative period. 
Postoperative intra-abdominal bleeding is most often a tech-
nical problem, arising from vascular anastomoses or extensive, 
raw peritoneal surfaces. Certainly, coagulation should be nor-
malized if postoperative bleeding occurs; if bleeding is proved, 
the origin should be presumed surgical and managed as such 
by early exploration. 
Biliary Complications 
Continuity of the biliary axis is preserved in multivisceral and 
cluster grafts as well as the modified liver/small-bowel graft. 
The standard liver/small-bowel graft requires a Roux-en-Y 
choledochojejunostomy. Correspondingly, these grafts can re-
sult in biliary system-related surgical complications (Le., leaks 
and obstructions). 
Biliary leaks usually occur within the first 2 weeks after 
liver/small-bowel transplantation and may herald their pres-
ence with bilious drainage from the abdominal wound or 
drains or merely with unexplained sepsis. The response to 
external bilious drainage should be immediate exploration 
with surgical revision of the biliary dehiscence. In the case of 
unexplained sepsis in any intestinal transplant recipient, all 
surgical anastomoses should be radiographically inspected 
(with percutaneous cholangiography); if leakage is suspected, 
the anastomoses should be openly revised. There is no place 
for percutaneous diversion of biliary or intestinal leakage in 
these patients, because both wound healing and antimicrobial 
immunity are impaired by multimodal immunotherapy. 
Biliary obstruction generally follows an anastomotic stric-
ture and is a delayed complication, but any clinical picture 
that resembles cholangitis or biliary obstruction should be 
investigated with cholangiography to prove patency, regard-
less of the timing after transplantation. 
Vascular Complications 
Major arterial thrombosis is a disastrous complication that 
leads to massive necrosis of the organs correspondingly sup-
plied. Elevation of hepatic enzymes and pallor of the intestinal 
stoma are accompanied by clinical deterioration, fulminant 
sepsis, and hepatic coma_ Isolated small-bowel grafts can be 
removed with the expectation of patient recovery; however, 
in patients with composite grafts, the event is usually fatal 
unless early retransplantation can be performed. Patency of 
the arteries can be rapidly confirmed with Doppler ultrasound 
examination. 
Because the superior mesenteric vein/portal vein axis is 
preserved in the composite grafts. venous outflow thrombosis 
is less likely to occur in these recipients. Isolated small-bowel 
grafts have an anastomosis of these veins that can potentially 
occlude. Ascites. stomal congestion. and, ultimately, mesen-
teric infarction would be the end result. 
Neither of these problems produces subtle clinical signs. 
and diagnosis should be prompt and obvious. In our series. 
isolated thrombosis of the hepatic artery has occurred in a 
pediatric recipient of a liver/small-bowel graft, with conse-
quent hepatic gangrene. This patient required retransplanta-
tion of the liver component of the graft. even though a full 
liver/small-bowel graft was desirable. 
Incomplete obstruction of major intlow or outtlow vessels 
•• ?if r n 
may be suspected on biopsy or based on clinical and labora-
tory evidence of organ dysfunction_ Contrast vascular x-ray 
studies are confirmatory, and the correction is surgical or, in 
some cases, with balloon dilatation. 
Gastrointestinal Complications 
Gastrointestinal bleeding after intestinal transplantation is an 
ominous sign that requires prompt attention. Rejection or 
infection is probable cause and should be immediately diag-
nosed or ruled out on the basis of enteroscopic biopsy results. 
The diagnosis of rejection relies not only on histologic evi-
dence but also on the endoscopic appearance (see Figs. 184-6 
and 184-7). Bleeding from ulcerated Epstein-Barr virus- or 
cytomegalovirus (CMV)-induced lesions can be easily differen-
tiated by gross endoscopic examination. Empirical therapy for 
rejection is not acceptable. 
Leakage of either the proximal or distal gastrointestinal 
anastomosis can occur in any recipient, but it is more com-
mon in children than in adults. Any fresh surgical margin, 
including native duodenal and colonic stumps and gastros-
tomy sites, are vulnerable to poor wound healing and subse-
quent leakage. Presentation is often dramatic (florid sepsis), 
with confirmation by radiologic contrast imaging. Surgical 
revision, evacuation of peritoneal soilage, and often reexplora-
tion are required to eliminate the contamination effectively. 
Again, sepsis without an obvious source should prompt the 
performance of contrast studies to document the integrity of 
all gastrointestinal anastomoses; if the findings are inconclu-
sive, diagnostic laparotomy is indicated. 
Native gastric atony and pylorospasm that produce early 
satiety or vomiting are common and self-limiting. The evolu-
tion of motility patterns in the denervated allograft intestine 
is not fully understood, although it is clear that various patho-
logic processes may alter the individual baseline_ Hypermo-
tility of the allograft intestine occurs early after transplanta-
tion; in the absence of rejection or bacterial overgrowth, it 
can be controlled with agents such as paregoric, loperamide, 
or pectin. Sudden changes in intestinal motility, particularly 
when accompanied by abdominal distention and vomiting in 
the case of decreased motility, should initiate a search for 
rejection. 
Infections 
The frequency of infectious complications is high and is re-
sponsible for significant morbidity and mortality after intesti-
nal transplantation. This retlects the relatively higher level of 
immunosuppression required to maintain the graft in these 
intestinal reCipients. Other predisposing factors include the 
severity of the preoperative liver failure and the presence of 
intra-abdominal, pulmonary, or intravenous line-induced sep-
sis before transplantation. Also, technically more difficult 
transplantation procedures with increased operative time, 
transfusion requirements, and likelihood of reexploration re-
flect the advanced disease of these patients. Recipients of 
small-bowel grafts have the lowest incidence of complications 
because of the more elective nature of their candidacy. 
Infectious pathogens include bacteria. fungi, and viruses. 
Infections are related (in order of frequency) to intravenous 
lines, the abdominal wound, deep abdominal abscesses, peri-
tonitis. and pneumonia. Bacterial translocation in grafts dam-
aged by rejection illustrates the need for concomitant antire-
jection and antimicrobial therapy and is a frequent source of 
infection. 
Of the bacterial pathogens. staphylococci and enterococci 
are common. whereas gram-negative rods usually accompany 
polymicrobial infections. Not uncommonly, separate sources 
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of infection occur simultaneously, or mixed infections from 
the same source are present. This leads to multiple antibiotic 
regimens and sets the stage for the development of resistant 
organisms. Particularly problematic has been the nascent 
strain of panresistant enterococci. Persistence of a physiologic 
hyperdynamic state in a patient being treated for proven infec-
tion should raise the suspicion of retained phlegmonous mate-
rial in the abdomen or the possibility of rejection.39 
Fungal infections become problematic after heavy treatment 
of rejection. massive antibiotic usage. intestinal leaks, and 
multiple surgical explorations. We routinely employ low-dose 
amphotericin B prophylaxis in patients with these complica· 
tions. Established fungal infections require long·term, full-dose 
antibiotic therapy and reduction of immunotherapy. All recipi· 
ents with persistent sepsis are potential candidates for moder· 
ation of immunosuppressant dosages if no coexistent cellular 
rejection is present. However, complete withdrawal of immu· 
nosuppression has been impossible in this recipient popula· 
tion because of a high incidence of rebound rejection. which 
then reqUires augmentation of immunotherapy. 
Clinical CMV infection has occurred in 36% of intestinal 
graft recipients and often involves the allograft intestine. Al· 
though the incidence and distribution of disease, according 
to donor and recipient CMV serologic status. are similar in 
adults (44%) and children (31%), the clinical course has been 
dramatically better in children. Successful clinical manage· 
ment has been accomplished in 88% of episodes with gan· 
ciclovir alone or in combination with CMV·specific hype rim· 
munoglobulin. Immunosuppression was maintained at 
baseline and reduced only in the face of deteriorating clinical 
disease, thus indicating rebound rejection. '9 A CMV·positive 
donor graft transplanted into a CMV·negative recipient is a 
significant risk factor, but intense baseline immunosuppres-
sion with high tacrolimus levels and cumulative doses of 
pulse steroids is a constant feature.'o Clinical presentation 
has generally been enteritis of variable severity with focal 
ulcerations and bleeding (Fig. 184-8) (see Color Plate). We 
currently avoid CMV·positive grafts only for CMV·negative can· 
didates who are awaiting isolated intestinal grafts. However. 
CMV-negative candidates awaiting the larger composite grafts. 
because they are at risk for death from liver failure. may still 
receive a CMV·positive graft.'" 
Less commonly, respiratory syncytial virus. adenovirus. and 
paraintluenza virus have occurred in children. All viral infec-
tions are opportunistic and have as a "common denominator" 
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the need for aggressive treatment of rejection episodes in 
complicated patients with high Acute Physiologic and Chronic 
Health Evaluation (APACHE) scores. 
Post·transplantation lymphoproliferative disease (PTLD) as-
sociated with the Epstein·Barr virus has occurred in 20% of 
all patients, with children (27%) being at a Significantly higher 
risk than adults (11 %). Presentation varies from totally asymp-
tomatic observations at routine endoscopy, nonspecific intesti· 
nal and systemic symptoms, bleeding, lymphadenopathy, and 
tumors, to fulminant disease. Risk factors other than age in· 
cluded the type of graft, splenectomy, and the use of OKT3. 
Therapy included the reduction and withdrawal of immuno-
suppression, antivirals (ganciclovir. acyclovir, hyperimmuno-
globulin), cytokines (interferon·alfa), and chemotherapy. How· 
ever the disease was lethal in 45% of our patients. Rebound 
rejection was a significant contributor to mortality.30· 36 ... 
Graft·Versus·Host Disease 
Skin changes consistent with graft·versus-host disease were 
confirmed by histopathologic criteria in five of our patients 
(5%), only one of whom had received adjunct bone marrow. 
This was confirmed by immunohistochemical studies visualiz· 
ing donor cell infiltration into the lesions on two occasions. 
One child died with hereditary immunoglobulin (IgG and IgM) 
deficiency;' and one adult had a complex chronic GVHD in 
association with PTID. All other cases have been self·limited 
and resolved spontaneously. 
Present Status and Future 
The causes of graft and patient loss are invariably multifacto-
rial and complex. The evolution of technical and clinical 
management factors have improved outcome. However, the 
interplay between the need for high levels of immunosuppres-
sion, the high incidence of immunosuppression, the high 
incidence of rejection, and the opportunistic infections conse· 
quent to this remain the major stumbling blocks to further 
progress. 
The experience accumulated over the last 8 years of this 
study has allowed the development of clinical and surgical 
strategies that has benefited a very clinically complex group 
of patients. Our reserved optimism is taken in light of previous 
experience with intestinal transplantation as well as the grim 
outcome of patients not receiving transplants. Nonetheless. 
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Figure 184-8. A. Endoscopic appearance of cytome~tovira[ enteritis is characterized by hyperemic erosions. B. The diaRl10Sis was conftnned 
hislOlo!(ically by the presence of characteristic inclusions. by stainin!( lor virJI anti!(ens. or both. Note the focal neutrophilic intlammation. 
(lmmunoperoxidase tor cvtome~atovirus anti~ens. x :\<;0.) (See Color Plate.) 
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Figure 184-9. Patient survival with age distribution. (From Abu-
Elmagd K. Reyes], Todo S, et al: Clinical intestinal transplantation: 
New perspectives and inununologic considerations. ] Am Coil Surg 
1998; 186:512-527.) 
the overall actuarial survival at 1 and 5 years has been 72% 
and 48%, respectively, with full nutritional support having 
been achieved in 91% of surviving patients. Improved results 
were achieved in the pediatric population between 2 and 18 
years of age (65% at 5 years)36 (Fig. 184-9). 
The transplantation of the isolated intestinal graft has pro-
vided better patient survival at all follow-up times. However, 
because of a higher incidence of rejection with this type of 
graft, the long-term outcome of all types of grafts (isolated 
intestine or composite grafts) has been similar and is estimated 
at about 40% at 5 years.\O· 36 (Fig. 184-10). 
Although the augmentation of donor leukocyte chimerism 
with bone marrow infusion did not alter patient or graft 
survival, it was not responsible for any significant morbidity, 
thus establishing its safety as an adjunct procedure. It has 
provided insights into the fate of the coexisting leukocyte 
populations (donor or recipient); however, further immuno-
modulatory strategies will be necessary to advance the field 
of intestinal transplantation. 
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Figure 184-10. Graft survival with intestine: alone. or as a 
composite with the liver allograft. (From Abu-Elmagd K. Reyes J, 
Todo S. et al: Clinical intestinal transplantation: New pe:rspectives 
3nd immunologiC considerations. J Am Coli Surg 1<)<)8: 
186:512-527.) 
Under the best of circumstances, the outlay of financial 
and time expenditures in composite and isolated small-bowel 
transplant recipients is impressive. For best possible results, 
candidates who have optimal nutritional status and who are 
free of active infection should be selected. Donor organs 
should be discarded if they are less than perfect. Even with 
technically perfect operations, the managing physician should 
expect a panoply of postoperative difficulties and should be 
prepared to support these patients fully for an indefinite pe-
riod. Managing the balance between excessive and inadequate 
immunosuppression in the face of potentially virulent infec-
tions, the pursuit of rejection and sources of infection, and 
maintenance of comprehensive critical care support are the 
most challenging tasks_ 
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In Chapter 175, a detailed history of organ transplantation is 
provided. In order to foster the appreciation and understand-
ing of the forces that will drive advances in transplantation 
into the next century, this chapter focuses on a few of the 
past developments in transplantation that have helped to 
shape current transplant practices (Fig. 185-1). The beginning 
of solid-organ transplantation can be traced back to the techni-
cal achievement of Alexis Carrel'; in 1902, he described the 
techniques of vascular anastomosis. thus ushering in accounts 
of autologous and homologous transplantation_ Although a 
number of animal-ta-human kidney transplants were reported 
in the ensuing three decades. a human donor organ was not 
used until 1933, by the Russian surgeon Voronoy.l This and 
other attempts at using human kidneys for transplantation 
failed owing to acute tubular necrosis and rejection. The first 
successful human transplant was performed on December 23, 
1954, by the Boston team of Moore, Murray, Merrill, and 
Harrison. j The transplantation of an identical twin kidney 
from one brother to another was the immunologic advantage 
that distinguished the early successes in kidney transplanta-
tion from those that otherwise were doomed to fail. 
Gibson and Medawar ascribed an immunologic basis to the 
rejection of tissues between ~enetically nonidentical individu-
als. In 1960, Caine and Murray' used azathioprine, developed 
several years earlier by Burroughs-Wellcome. in attempts to 
gain success in unrelated kidney transplantation using immu-
nosuppreSSive agents. Stanl and colleagues" then modified 
the immunosuppressive regimen by adding corticosteroids for 
rejection and began routinely to achieve success. This success 
led to growing attempts at human kidney transplantation. 
aggravating the shortage of organs to use for transplantation. 
A number of animal-to-human transplantations were at-
tempted. The longest survivor was a 23-year-old woman who 
lived for 9 months after receiving kidneys from a chimpanzee.7 
In 1968. the Ad Hoc Committee of the Harvard School of 
Medicine proposed the concept of "irreversible coma."" Fur-
ther clarification of the pathophysiology of irreverSible brain 
stem injury and subsequent somatic death followed. as did 
objective criteria to document irreversible brain injury. The 
brain death concept has eventually been accepted throughout 
the United States (see Chapter 17·4). TIle details of brain death 
evaluation and certification vary from state to state but require 
a clinical picture of (1) coma not due to drug overdose (e.g .• 
alcohol) or to physical reasons (c.g .. hypothermia) and (2) 
lack of cranial nerve retlexes. Conlirmatory tests are used to 
document the absence of blood flow to the brain and the lack 
of cerebral and brain stem electric activity. The use of brain-
dead donors. with optimal hemodynamic parameters. offers 
the possibility of better-quality olWlns with minimum damage 
from warm ischemia. It has also allowed procurement of 
extrarenal organs in a systematic manner:' Another improve-
ment in the area of donor management was the development 
of preservation solutions. tirst Collins solution'u and currently 
